Loading...
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary t...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wiley Subscription Services, Inc., A Wiley Company
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2958458/ https://ncbi.nlm.nih.gov/pubmed/20473913 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.25423 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|